



Press release

Publication of the annual report for financial year 2014

Sophia Antipolis, France – April 15, 2015 - MEDIAN Technologies (ALMDT.PA), a leading medical imaging solutions and service provider for image interpretation and management in oncology clinical trials, cancer screening programs and routine practice in oncology, informs its shareholders and the financial community that its annual financial report on the accounts for the year ended December 31, 2014 was made public and filed with the AMF.

The annual financial report is available on the company's website: www.mediantechnologies.com

ALMDT
LISTED
ALTERNEXT

About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world's largest CRO (Contract Research

Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”



Contacts

<p>MEDIAN Technologies Fredrik Brag, CEO +33 4 92 90 65 82 fredrik.brag@mediantechnologies.com</p>	<p>Press ALIZE RP Caroline Carmagnol Sophie Colin + 33 1 44 54 36 66 median@alizerp.com</p>	<p>Investors ACTIFIN Ghislaine Gasparetto ggasparetto@actifin.fr +33 1 56 88 11 11</p>
--	---	--